Authors: Danielle Dalby, Oxford Global (UK)
Oxford Global Conference’s 2nd Annual Advances in Immuno-Oncology Congress saw over 200+ delegates working within the immune-oncology field come together to discuss the latest in the discovery of immune-oncology therapeutic areas, pre-clinical and clinical studies, screening, assays and modelling. The congress took place on the 15-16 May 2017 in central London and once again received glowing feedback from the industry’s most senior level peers.
The congress agenda was jam packed with interesting talks, which ran across four interactive streams:
- Discovery of Immuno-Oncology Therapies
- Pre-clinical Immuno-Oncology
- Screening, Assays and Modelling in Immuno-Oncology
- Immuno-Oncology: Therapeutic Approaches, Clinical Research and Clinical Trials
Engineered-Immune Cells as Treatments for Cancer Patients – The Past, Presence & Future
Vice President, Head of Oncology Cell Therapy DPU, Oncology R&D, GlaxoSmithKline
The Development of Adoptive T Cell Therapies and our use of them to treat Solid Tumours
Vice President Pipeline Operations, Adaptimmune
Oncolytic Viruses as Single Agent or Combination Immunotherapeutics
Professor of Medical Oncology, University of Surrey
Senior level delegates came together to discuss current & future research and exchange experience and knowledge from within the industry. Attendees were very positive about the range of talks available to them: “The topics covered at the Congress were excellent – there was a good combination of preclinical, biomarkers, clinical and new technologies,” commented Director of Immuno Monitoring & Biomarker Development, Aduro BioTech (CA, USA).
This congress also gave delegates and sponsors the chance to network with like minded peers across the two-days in a relaxed environment: “The opportunity to network with experienced colleagues in the field and to network for potential collaborations was great!” Research Technician, University College London “The event was fantastic for networking with attending delegates – there were many like-minded folks present,” explained Consultant to Histologix, Director of Immune Insight Limited, Histologix (UK).
New to 2017 Oxford Global ran several round table discussions. We had some fantastic topics discussed, including:
- How can we Optimise Patient & Disease Selection for the use of Checkpoint Inhibitors?
- Biomarker & Companion Diagnostic Development in Immuno-Oncology
- Developing Immunotherapy Combination Treatment Strategies
- What Comes Next When the Checkpoint Inhibitor Hype is Over?
- Next Generation Antibodies in Immuno-Oncology
- The Future of Cell Therapies in Immuno-Oncology
Each table was a hive of activity, the moderators were kept busy organizing the flow of discussion!
Our sponsors for 2017 were extremely happy with the event:
“There was a good mixture of innovative and clinical talks by a diverse range of speakers. The event was well organised and the Oxford Global staff were attentive.” Vice President, R&D Research Biology, DiscoverX
“The diversity of the talks and the quality of speakers was great. The Oxford Global team were very friendly and the organisation was good.” Technical Sales Correspondent, Bio-Techne
Following the event, we analyse statistics and feedback from attendees, and we are proud to announce that we achieved an “Above Average” or “Excellent” rating in all categories including:
- Relevance and Quality of the Delegates and Solution Providers
- Organisation of the One-to-one Meetings
- Format and Content of the Congress Agenda
This is great news for everyone involved in the production of the 2nd Annual Advances in Immuno-Oncology Congress.
After the success of this year’s event, Oxford Global Conferences are pleased to announce that we will be hosting our 3rd Annual Advances in Immuno-Oncology Congress, once again in London in May 2018. For further information on attending or sponsoring the event, please contact Danielle Dalby on +44 1865 248455 or by email on email@example.com